DGAP-Adhoc

Teprotumumab Restarts Clinical Development in New Indication

Genmab A/S

11.06.2013 21:54

Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group
AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Company Announcement

-- Teprotumumab (RG1507) to be investigated for new indication
-- River Vision Development Corporation to conduct clinical development under
a license from Roche

Copenhagen, Denmark; June 11, 2013 - Genmab A/S (OMX: GEN) announced today that
teprotumumab (RG1507), an antibody developed by Genmab under our collaboration
with Roche, will restart clinical development in a Phase 2 study in patients
with active thyroid eye disease. Clinical development will be conducted by
River Vision Development Corporation, who licensed teprotumumab from Roche.

'In drug development, it's often possible to take what was learned about a
product in its initial development and apply it to new indications. We are
pleased that River Vision will resume clinical development of teprotumumab for
the potential treatment of ophthalmic conditions,' said Jan van de Winkel,
Ph.D., Chief Executive Officer.

Under our collaboration with Roche, Genmab will receive milestones as well as
royalty payments on successful products.

River Vision Development Corporation is a private company focused on
ophthalmology.

Today's news does not affect Genmab's financial guidance for 2013.

About Teprotumumab
Teprotumumab is a fully human antibody that targets the Insulin-like Growth
Factor-1 Receptor (IGF-1R) which is a well validated target. Teprotumumab was
previously investigated in various cancer indications.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: [phone]; M: [phone]; E: [e-mail]